RFA-AI-24-080: Broad Spectrum Products Against Multiple Neurotoxin Botulinum Serotypes (R61/R33 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2024.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on May 2, 2025.
From the official notice on Grants.gov, last changed December 11, 2024. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR61 / R33
- Clinical trialsNot allowed
- Funded byNIAID
- Median yearly award$501,832
- Typical project length2 years
- R61, Exploratory/Developmental Phase I. The first phase of a phased award. Moving on to the R33 phase depends on meeting agreed milestones. Other open R61 notices.
- R33, Exploratory/Developmental Grant Phase II. The second phase of a phased award, usually following an R61 or R21 phase. Other open R33 notices.
Projects funded under RFA-AI-24-080 were run by National Institute of Allergy and Infectious Diseases (NIAID, 6 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-AI-24-080 in the NIH Guide.
Key dates
| Posted | December 11, 2024 |
|---|---|
| Deadline | May 2, 2025 |
| Archived by Grants.gov | June 7, 2025 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Is this a realistic fit?
- Most of the program's money (67% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this notice of funding opportunity (NOFO) is to support the development of improved products for treating Botulinum Neurotoxin (BoNT) intoxication. Development of products that can reverse BoNT intoxication are highly encouraged. This NOFO will use a milestone-driven, biphasic award mechanism. Transition to the R33 phase will depend on the successful completion of specific milestones during the R61 phase.
Funded under RFA-AI-24-080 so far
NIH funded 6 projects under RFA-AI-24-080 in fiscal 2026, at 5 institutions. The median yearly award was $501,832.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Next Generation pan-serotype,antitoxin for botulinum neurotoxin exposures | Tufts University Boston | 2026 | $531,688 |
| Improved Aminopyridine Analogs for Symptomatic Treatment of Botulism | Wake Forest University Health Sciences | 2026 | $480,448 |
| Engineering broadly cross-reactive monobodies to reverse botulinum intoxication | The Scripps Research Institute | 2026 | $501,137 |
| Develop delivery systems and therapeutic proteins for reversal of botulinum neurotoxin intoxication | Boston Children's Hospital | 2026 | $534,000 |
| Next-generation protein neurotherapeutics for botulism poisoning | Wake Forest University Health Sciences | 2026 | $502,528 |
| Fully recombinant, highly potent heptavalent botulinum antitoxin with ambient temperature stability | University of California, San Francisco | 2026 | $491,985 |
Who has won Allergy and Infectious Diseases Research grants before
From fiscal 2021 to 2025, Allergy and Infectious Diseases Research (93.855) awarded $22 billion across 13,282 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Fred Hutchinson Cancer Center | Washington | 85 | $938 million |
| Duke University | North Carolina | 230 | $781 million |
| University of California, Los Angeles | California | 138 | $745 million |
| The Johns Hopkins University | Maryland | 321 | $668 million |
| Emory University | Georgia | 282 | $650 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-AI-24-080 still open?
No. It closed on May 2, 2025.
Who can apply for Broad Spectrum Products Against Multiple Neurotoxin Botulinum Serotypes (R61/R33 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Broad Spectrum Products Against Multiple Neurotoxin Botulinum Serotypes (R61/R33 Clinical Trial Not Allowed)?
Closed May 2, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-AI-24-080?
NIH RePORTER lists 6 projects funded under RFA-AI-24-080 in fiscal 2026, at 5 institutions. The most were at Wake Forest University Health Sciences, Tufts University Boston, The Scripps Research Institute.
Who has won Allergy and Infectious Diseases Research grants before?
The largest recipients over five fiscal years were Fred Hutchinson Cancer Center, Duke University, University of California, Los Angeles. The program made 13,282 awards worth $22 billion in that time.
Similar open grants
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
- NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
- Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)
- HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)